These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18949462)

  • 21. Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging.
    Sultzer DL; Melrose RJ; Riskin-Jones H; Narvaez TA; Veliz J; Ando TK; Juarez KO; Harwood DG; Brody AL; Mandelkern MA
    Am J Geriatr Psychiatry; 2017 Apr; 25(4):342-353. PubMed ID: 28162919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.
    Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.
    Oboshi Y; Kikuchi M; Terada T; Yoshikawa E; Bunai T; Ouchi Y
    J Alzheimers Dis; 2016 May; 53(3):817-30. PubMed ID: 27258412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems.
    Wang D; Noda Y; Zhou Y; Mouri A; Mizoguchi H; Nitta A; Chen W; Nabeshima T
    Neuropsychopharmacology; 2007 Jun; 32(6):1261-71. PubMed ID: 17133263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.
    Nordberg A
    Biol Psychiatry; 2001 Feb; 49(3):200-10. PubMed ID: 11230871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
    Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
    Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
    Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholinergic Changes in Aging and Alzheimer Disease: An [18F]-F-A-85380 Exploratory PET Study.
    Lagarde J; Sarazin M; Chauviré V; Stankoff B; Kas A; Lacomblez L; Peyronneau MA; Bottlaender M
    Alzheimer Dis Assoc Disord; 2017; 31(1):8-12. PubMed ID: 27680780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
    Doll F; Dolci L; Valette H; Hinnen F; Vaufrey F; Guenther I; Fuseau C; Coulon C; Bottlaender M; Crouzel C
    J Med Chem; 1999 Jun; 42(12):2251-9. PubMed ID: 10377231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
    Bokde AL; Karmann M; Teipel SJ; Born C; Lieb M; Reiser MF; Möller HJ; Hampel H
    J Clin Psychopharmacol; 2009 Apr; 29(2):147-56. PubMed ID: 19512976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.
    Noda Y; Mouri A; Ando Y; Waki Y; Yamada SN; Yoshimi A; Yamada K; Ozaki N; Wang D; Nabeshima T
    Int J Neuropsychopharmacol; 2010 Nov; 13(10):1343-54. PubMed ID: 20219155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
    Samochocki M; Zerlin M; Jostock R; Groot Kormelink PJ; Luyten WH; Albuquerque EX; Maelicke A
    Acta Neurol Scand Suppl; 2000; 176():68-73. PubMed ID: 11261808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380.
    Le Foll B; Chefer SI; Kimes AS; Shumway D; Goldberg SR; Stein EA; Mukhin AG
    J Nucl Med; 2007 Sep; 48(9):1492-500. PubMed ID: 17704243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
    Coyle JT; Geerts H; Sorra K; Amatniek J
    J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
    Moriguchi S; Zhao X; Marszalec W; Yeh JZ; Fukunaga K; Narahashi T
    Neuroscience; 2009 May; 160(2):484-91. PubMed ID: 19272425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.
    Dubroff JG; Doot RK; Falcone M; Schnoll RA; Ray R; Tyndale RF; Brody AL; Hou C; Schmitz A; Lerman C
    J Nucl Med; 2015 Nov; 56(11):1724-9. PubMed ID: 26272810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
    Samochocki M; Höffle A; Fehrenbacher A; Jostock R; Ludwig J; Christner C; Radina M; Zerlin M; Ullmer C; Pereira EF; Lübbert H; Albuquerque EX; Maelicke A
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1024-36. PubMed ID: 12649296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.